[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369732-105":59,"doc-detail-369732-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","utility-of-germline-somatic-and-ctdna-testing-in-adults-with-cancer","Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer","","A narrative review synthesizes international evidence on the clinical utility of comprehensive genomic profiling (CGP) across cancer prevention, detection, and treatment. Literature searches across three databases identify germline and somatic variant frequencies in adult cancers and how these variants inform diagnosis, management, and outcomes. Results from 95 studies show ~10% pathogenic germline variants, substantial treatment impact from actionable somatic variants, and feasibility of ctDNA assays for sensitive, serial monitoring and residual disease assessment. Conclusions emphasize need for frontline CGP given underuse of matched therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/utility-of-germline-somatic-and-ctdna-testing-in-adults-with-cancer/369732/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/utility-of-germline-somatic-and-ctdna-testing-in-adults-with-cancer/369732.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review aim to evaluate about comprehensive genomic profiling (CGP) in cancer?","Question",{"text":112,"@type":113},"It aims to capture current international evidence on the clinical utility of CGP for cancer prevention, detection, and treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key proportions of adults with cancer were found to carry pathogenic germline variants?",{"text":117,"@type":113},"Consolidated results indicate pathogenic germline variants occur in about 10% of adults with cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"How are ctDNA assays positioned for clinical use in the reviewed evidence?",{"text":121,"@type":113},"ctDNA assays are described as feasible and sensitive, supporting relatively non-invasive sample collection, serial monitoring of residual disease, and/or treatment response—especially for cancers with inaccessible or unknown primary sites.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369732,1790331654,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nUtility of Germline, Somatic and ctDNA Testing in Adults With Cancer  \nEmily DeBortoli1 | Ella McGahan1 | Tatiane Yanes1 | Jennifer Berkman1 | Lauren G. Aoude2 | Amelia K. Smit3,4  | Akira Gokoolparsadh5 | Azure Hermes6 | Lyndsay Newett6 | Mackenzie Bourke7 | Susan Hanson8 | Helen Hughes8 | Oliver Hofmann9 | Ilias Goranitis7,10 | Rebekah McWhirter11 | Vivienne Milch8,12 | Julia Steinberg3 |  \nAideen McInerney-Leo1   \n1Dermatology Research Centre, The Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia | 2Frazer Institute, The University of Queensland, Brisbane, QLD, Australia | 3The Daffodil Centre, The University of Sydney, a Joint Venture With Cancer Council New South Wales, Sydney, New South Wales, Australia | 4Faculty of Medicine and Health, Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia | 5Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health Ethics, The University of Sydney, Sydney, New South Wales, Australia | 6National Centre for Indigenous Genomics, Australian National University, Canberra, Australia Capital Territory, Australia | 7Economics of Genomics and Precision Medicine Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia | 8Cancer Australia, Sydney, New South Wales, Australia | 9University of Melbourne Centre for Cancer Research, Melbourne, Victoria, Australia | 10Australian Genomics, Murdoch Children's Research Institute, Melbourne, Victoria, Australia | 11School of Law, Australian National  \nUniversity, Canberra, Australia | 12Caring Futures Institute, Flinders University, Adelaide, South Australia, Australia Correspondence: Aideen McInerney-Leo ([a.mcinerney@uq.edu.au](a.mcinerney@uq.edu.au))  \nReceived: 3 November 2024 | Revised: 30 April 2025 | Accepted: 11 July 2025  \nFunding: J.B., E.D. and E.M. are [supported by Australian Government Research Training Program Scholarships. T.Y. is](supported by Australian Government Research Training Program Scholarships. T.Y. is) funded by a National Health and Medical Research Council (NHMRC) EL1 Grant (APP2009136). [J.S. is](J.S. is) the recipient of a Cancer Institute NSW Career Development Fellowship (2022/ CDF1154). [A.M.-L. is](A.M.-L. is) [supported by a University of Queensland Faculty of Medicine Fellowship. A.S. is](supported by a University of Queensland Faculty of Medicine Fellowship. A.S. is) supported by a NHMRC Synergy grant (\\#2009923). Cancer Australia provided funding that partially supported this study and contributed to the study conception and scope.  \nKeywords: cancer | ctDNA | genetics | genomics | germline | narrative review | somatic  \nABSTRACT  \nBackground and Aim: Historical genetic sequencing of specific cancer variants has been superseded by comprehensive genomic profiling (CGP). This narrative review aimed to capture current international evidence on the clinical utility of CGP for cancer prevention, detection and treatment.  \nMaterials and Methods: A literature search of three databases was performed to identify key studies on the frequency of germline and somatic variants in adult cancers and the extent to which they inform diagnosis, management and outcome. Findings were inductively mapped and narratively synthesised.  \nResults: Consolidated results from 95 original research papers showed that pathogenic germline (familial) variants are found in~10% of adults with cancer, of whom 53%–61% are offered germline genotype-directed treatment. Importantly, 50% of germline carriers would not have satisfied the eligibility criteria for genetic testing and/or reported a negative family history. Actionable somatic variants occur in 27%–88% of cases, which markedly impact the diagnosis for cancers of unknown primary. Matched treatments were identified for 31%–48% of cancer patients, of whom 33%–45% received it. Response and surv","cbCaisCZ9zxN0OGb","https://ap.wps.com/l/cbCaisCZ9zxN0OGb","pdf",1990745,17,"English","# Abstract\n## Background and Aim\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What does the review aim to evaluate about comprehensive genomic profiling (CGP) in cancer?\",\"answer\":\"It aims to capture current international evidence on the clinical utility of CGP for cancer prevention, detection, and treatment.\"},{\"question\":\"What key proportions of adults with cancer were found to carry pathogenic germline variants?\",\"answer\":\"Consolidated results indicate pathogenic germline variants occur in about 10% of adults with cancer.\"},{\"question\":\"How are ctDNA assays positioned for clinical use in the reviewed evidence?\",\"answer\":\"ctDNA assays are described as feasible and sensitive, supporting relatively non-invasive sample collection, serial monitoring of residual disease, and/or treatment response—especially for cancers with inaccessible or unknown primary sites.\"}]","Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer | PDF",1790184263,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40bdbc0132af84b04b350b5251abbd6b.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19af3863f419752404a8eeb96bc98128.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a9d4505efac4aa84edaefdda6a38c39.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cdc039ca04aafbb086f40ed96b3b7e7.webp",980,1287]